Progress on cholesterol metabolism and non-alcoholic steatohepatitis

doi:10.16352/j.issn.1001-6325.2022.07.1134

Abstract

Abstract: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD). Cholesterol is an essential substance for biological process. Intestinal absorption of dietary cholesterol, as well as circulating lipoprotein exchange, intracellular cholesterol synthesis and metabolism influence hepatic lipid metabolism. It is indicated that the dysfunction of organelles and the secretion of inflammatory cytokines contributed to the activation of cholesterol-loaded macrophage. Besides, cholesterol and bile acid metabolism can also trigger to the development and progression of NASH.

Key words: cholesterol, non-alcoholic steatohepatitis, macrophage, inflammation, bile acid

CLC Number:

R589

LI Xiao-xiao, SHU Xiang-bing, ZHANG Li. Progress on cholesterol metabolism and non-alcoholic steatohepatitis[J]. Basic & Clinical Medicine, 2022, 42(7): 1134-1138.

References 21

[1]	Nihei W, Nagafuku M, Hayamizu H, et al. NPC1L1-dependent intestinal cholesterol absorption requires ganglio-side GM3 in membrane microdomains[J]. J Lipid Res, 2018, 59: 2181-2187.
[2]	Zuo H, Su X, Jin Y, et al. Transthyretin regulated by linc00657/miR-205-5p promoted cholesterol metabolism by inducing SREBP2-HMGCR and inhibiting LXR alpha-CYP7A1[J]. Arch Med Res, 2020, 51: 317-326
[3]	McGettigan B, McMahan R, Orlicky D, et al. Dietary lipids differentially shape nonalcoholic steatohepatitis progression and the transcriptome of Kupffer cells and infiltrating macrophages[J]. Hepatology, 2019, 70: 67-83.
[4]	Chen HW, Yen CC, Kuo LL, et al. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells[J]. Toxicol Appl Pharmacol, 2020, 393: 114941. doi: 10.1016/j.taap.2020.114941.
[5]	Bakke SS, Aune MH, Niyonzima N, et al. Cyclodextrin reduces cholesterol crystal-induced inflammation by modulating complement activation[J]. J Immunol, 2017, 199: 2910-2920.
[6]	Ho CM, Ho SL, Jeng YM, et al. Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease[J]. J Inflamm, 2019, 16: 7. doi: 10.1186/s12950-019-0211-5.
[7]	庄红, 张苏川, 刘慧地, 等. 沉默CXCL12抑制ox-LDL小鼠巨噬细胞系RAW264.7泡沫化和凋亡[J]. 基础医学与临床, 2021, 41:219-224.
[8]	Ioannou GN, Van Rooyen DM, Savard C, et al. Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH[J]. J Lipid Res, 2015, 56: 277-285.
[9]	Yu Y, Liu Y, An W, et al. STING-mediated inflamma-tion in Kupffer cells contributes to progression of nonalcoholic steatohepatitis[J]. J Clin Invest, 2019, 129: 546-555.
[10]	Dang EV, McDonald JG, Russell DW, et al. Oxysterol restraint of cholesterol synthesis prevents AIM2 inflammasome activation[J]. Cell, 2017, 171: 1057-1071.
[11]	Domínguez-Pér milton C, Mortensen R, et al. Trafficking of cholesterol to the ER is required for NLRP3 inflammasome activation[J]. J Cell Biol, 2018, 217: 3560-3576.
[13]	Guo C, Chi,Z, Jiang D, et al. Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages[J]. Immunity, 2018, 49: 842-856.
[14]	Di Rocco M, Pisciotta L, Madeo A, et al. Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency[J]. Orphanet J Rare Dis, 2018, 13: 24. doi: 10.1186/s13023-018-0768-8.
[15]	Fiorucci S, Biagioli M, Sepe V, et al. Bile acid modu-lators for the treatment of nonalcoholic steatohepatitis (NASH)[J]. Expert Opin Investig Drugs, 2020, 29: 623-632.
[16]	Fiorucci S, Di Giorgio C, Distrutti E. Obeticholic acid: an update of its pharmacological activities in liver dis-orders[J]. Handb Exp Pharmacol, 2019, 256: 283-295.
[17]	Briand F, Brousseau E, Quinsat M, et al. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the diet-induced NASH (DIN) hamster model[J]. Eur J Pharmacol, 2018, 818: 449-456.
[18]	Carino A, Marchianò S, Biagioli M, et al. Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis[J]. Faseb J, 2019, 33: 2809-2822.
[19]	Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites[J]. Gut, 2021, 70: 761-774.
[20]	Beaumont M, Neyrinck AM, Olivares M, et al. The gut microbiota metabolite indole alleviates liver inflammation in mice[J]. Faseb j, 2018, 32: fj201800544. doi: 10.1096/fj.201800544.
[21]	Canyelles M, Tondo M, Cedó L, et al. Trimethylamine N-oxide: a link among diet, gut microbiota, gene regulation of liver and intestine cholesterol homeostasis and HDL function[J]. Int J Mol Sci, 2018, 19: 3228. doi: 10.3390/ijms19103228.

[1]	MENG Dequan, QIN Xin, CHEN Ling, QIN Jun. Polysaccharides from Atractylodes macrocephala koidz. inhibit inflammatory response in rat model of severe pneumonia [J]. Basic & Clinical Medicine, 2024, 44(9): 1263-1268.
[2]	JIANG Su, LYU Xinxiang, CUI Yanhong, LYU Liting, LI Dongxia. Therapeutic effect of evodiamine on atopic dermatitis in rat models [J]. Basic & Clinical Medicine, 2024, 44(9): 1256-1262.
[3]	QIAN Xifeng, HUA Lu. Inflammatory cells and vascular remodeling in pulmonary arterial hypertension [J]. Basic & Clinical Medicine, 2024, 44(8): 1080-1087.
[4]	GAO Chao, ZHANG Runhan, WANG Wei, ZHAO Manting, JIAO Yan, LI Zhe. Effect of artesunate on neuroinflammation in depressed mouse model by regulating cGAS-STING signaling pathway [J]. Basic & Clinical Medicine, 2024, 44(8): 1126-1132.
[5]	CHEN Xiaotian, CHEN Chong, LUO Yunping. Impact of MAFB on polarization and function of tumor associated macrophages [J]. Basic & Clinical Medicine, 2024, 44(7): 965-973.
[6]	SONG Boyuan, WU Xueli, LI Xueyuan, WANG Lisha, CHEN Yang. Dynamic transcriptomic analysis of macrophages infected with Salmonella typhimurium [J]. Basic & Clinical Medicine, 2024, 44(6): 779-785.
[7]	YUE Lingling, WANG Zihui, LI Xiaoqin, LI Lifeng, ZHANG Wancun, YU Zhidan. Regulation of host immune function by gut microbiota-derived secondary bile acids [J]. Basic & Clinical Medicine, 2024, 44(6): 887-891.
[8]	SHENG Qi, TONG Jin. The CXCL10/CXCR3 axis in acute respiratory distress syndrome [J]. Basic & Clinical Medicine, 2024, 44(6): 892-896.
[9]	ZHANG Diya, LI Yunfan, GUO Hongjiang, QIU Jiaxing, WANG Yucheng, JU Rui, GUO Lei. Glioma conditioned medium promotes glycolysis and phenotypic transformation in macrophages [J]. Basic & Clinical Medicine, 2024, 44(5): 599-605.
[10]	YE Yuxin, LI Huixian, YAN Tao, ZHANG Yun, SUN Yulin. Quantitative analysis of trace-level proteins for assessing inflammation through clinical sampling [J]. Basic & Clinical Medicine, 2024, 44(5): 690-698.
[11]	ZHAO Dong, ZHA Shiqian, WANG Yixuan, PAN Zhou, YU Wenzhen, HU Ke. Macrophage-to-myofibroblast transition promotes pulmonary fibrosis occurred in LPS-induced acute lung injury of mouse models [J]. Basic & Clinical Medicine, 2024, 44(3): 281-287.
[12]	YU Hanqiao, LI Chao, YU Yubin, FENG Lina, SHENG Xiaosheng, YE Xiaoxia, WANG Linyan. Inhibition of triggering receptor expressed on myeloid cells-1(TREM-1) attenuates chronic intermittent hypoxia-induced atherosclerosis in mouse models [J]. Basic & Clinical Medicine, 2024, 44(3): 368-373.
[13]	CHEN Weiwei, LIAO Huang, SHI Zhenhong, LUO Ying. FHL2 regulates THP-1 macrophage foaming through NF-κB signaling pathway [J]. Basic & Clinical Medicine, 2024, 44(2): 204-209.
[14]	LIANG Huiyong, WEI Qiuhui, DING Ya, PENG Xiaoqing, YAO Jing, SU Qijian. Cordycepin inhibits proliferation of human keratinocyte cell line HaCaT induced by TNF-α [J]. Basic & Clinical Medicine, 2023, 43(9): 1390-1393.
[15]	CHEN Xinjun, WANG Qinyu, CHEN Le, GU Chunyu, WU Zhuo. Pterostilbene reduces paraquat-induced pulmonary fibrosis in rat model [J]. Basic & Clinical Medicine, 2023, 43(9): 1383-1389.